An interventional study of Brain Interchange System in Epilepsy, sponsored by Mayo Clinic. Active, not recruiting at 2 sites in United States. Open to participants aged 3 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Epilepsy by Mayo Clinic — 5 open to participants now, 8 under way, none of them phase 3. Epilepsy · Mayo Clinic.
Among the 21 studies in Epilepsy by Mayo Clinic, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 15th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →5 of the 21 studies in Epilepsy by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 6+
Mayo Clinic · Sites in United States
Ages 18–50
Mayo Clinic · Sites in United States
Ages 3–70
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 3 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 1 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 8 across the 18 interventional studies, 50 across the 3 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
4 of the studies in Epilepsy by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06700356Mayo ClinicThalamus Seizure Detection With a Deep Brain Stimulator System | 2026-11 |
| NCT03946618Mayo ClinicNeurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy | 2027-02 |
| NCT06038929Mayo ClinicEffect of Vagal Nerve Stimulation on Gastric Motor Functions | 2027-07-31 |
| NCT06617845Mayo ClinicOptimizing Brain Stimulation Parameters | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Epilepsy by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overall, this study will investigate the functional utility of stereotyped HFOs by capturing them with a new implantable system (Brain Interchange - BIC of CorTec), which can sample neural data at higher rates >=1kHz and deliver targeted electrical stimulation to achieve seizure control. In contrast to current closed-loop systems (RNS), which wait for the seizure to start before delivering stimulation, the BIC system will monitor the spatial topography and rate of stereotyped HFOs and deliver targeted stimulation to these HFO generating areas to prevent seizures from occurring. If the outcomes of our research in an acute setting become successful, the investigators will execute a clinical trial and run the developed methods with the implantable BIC system in a chronic ambulatory setting.
High-frequency oscillations (HFOs) of intracranial EEG (iEEG) have the potential to identify the surgical resection area/seizure onset zone (SOZ) in patients with drug-resistant epilepsy. However, multiple reports indicate that HFOs can be generated not only by epileptic cerebral tissue but also by non-epileptic sites often including eloquent regions such as motor, visual, and language cortices. In this project, the initial evidence of a recurrent waveform pattern is presented that may be sufficient to distinguish pathological HFOs from physiological ones. Specifically, the investigators show that the SOZ repeatedly generates sets of stereotypical HFOs with similar waveform morphology whereas the events recorded from out of SOZ were irregular. This morphological pattern served as a robust neurobiomarker to isolate SOZ from other brain areas in multiple patients consistently. While these promising preliminary results are in place, the functional utility of stereotyped HFOs in a closed-loop seizure control system remains unknown. As of today, not much is known whether the stereotyped HFOs generated by the SOZ can be detected with an implantable system. If this can be achieved, then HFOs can be strategically translated as a neurobiomarker into closed-loop seizure control applications. The investigators hypothesize that pathologic stereotyped HFOs can be captured with the implantable Brain Interchange (BIC) system of CorTec and spatial topography of these events can be utilized by the implantable system to deliver targeted electrical stimulation to achieve seizure control. Using an acute setup within the epilepsy monitoring unit (EMU), this project will investigate the feasibility of capturing stereotyped HFO events using the new BIC system and compare the detection results to those obtained with the commercially available amplifier (Aim-1). If the first phase (Aim-1) of the study becomes successful, later in the second phase (Aim-2), once again in the EMU, the investigators will deliver targeted electrical stimulation to those brain sites associated with stereotyped HFOs using the BIC.
During the entire study, the BIC system will not be implanted but used externally to assess the neural data through externalized electrodes and then deliver closed-loop stimulation. If the outcomes of the research in an acute setting become successful, the investigators will execute a clinical trial and run our methods with the implanted BIC system in a chronic ambulatory setting.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with drug resistant epilepsy undergoing a surgical evaluation in the epilepsy monitoring unit
Device: Brain Interchange System
The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
Packet Loss Rate
Assessed by the percentage of transmitted data packets (a small unit of information that a device sends across a network) that were not successfully received and recorded by the BIC system in the epilepsy monitoring unit.
Time frame: Over 24 hours
Percentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings
The outcome was calculated as the proportion of HFO events detected by the clinical amplifier that were also retained in the BIC recording during the 24-hour EMU recording period. The reported value represents a percentage calculated from the total number of retained HFO events divided by the total number of HFO events detected by the clinical amplifier. Because this outcome measure is an event-based proportion calculated from counts of detected HFOs rather than a participant-level variable measured for each participant, a measure type of Number was used rather than a measure of central tendency.
Time frame: Over 24 hours
Accuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset Zone
Evaluated the ability of BIC-derived HFOs to localize the seizure onset zone during a 24-hour EMU recording.
Time frame: Over 24 hours
| Milestone | Epilepsy |
|---|---|
| Started | 15 |
| Completed | 13 |
| Not completed | 2 |
Assessed by the percentage of transmitted data packets (a small unit of information that a device sends across a network) that were not successfully received and recorded by the BIC system in the epilepsy monitoring unit.
| percentage of data packets | Epilepsy |
|---|---|
| Packet Loss Rate | 0.55 ± 0.33 |
The outcome was calculated as the proportion of HFO events detected by the clinical amplifier that were also retained in the BIC recording during the 24-hour EMU recording period. The reported value represents a percentage calculated from the total number of retained HFO events divided by the total number of HFO events detected by the clinical amplifier. Because this outcome measure is an event-based proportion calculated from counts of detected HFOs rather than a participant-level variable measured for each participant, a measure type of Number was used rather than a measure of central tendency.
| percentage of HFOs | Epilepsy |
|---|---|
| Percentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings | 82 |
Evaluated the ability of BIC-derived HFOs to localize the seizure onset zone during a 24-hour EMU recording.
| percentage | Epilepsy |
|---|---|
| Sensitivity | 84 |
| Specificity | 90 |
Collected over Adverse events were collected for during the time of study device use, approximately 24 hours.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epilepsy | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Age, Continuous(years) | Epilepsy |
|---|---|
| Mean | 31.87 ± 18.89 |
| Sex: Female, Male(Participants) | Epilepsy |
|---|---|
| Female | 7 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Epilepsy |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Epilepsy |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Epilepsy |
|---|---|
| United States | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Intracranial EEG + ECoG recorded from patients with epilepsy will be shared. The electrical signs of neural activity will be collected in the EMU for 24hrs. One stream of data will be digitized at 1kHz with 16bit resolution with the BIC system and the other stream with least a 2 kHz sampling frequency to capture HFOs reaching up to 500Hz. All collected data will be de-identified prior to data exchange. Patient data will be provided in a coded format that protects patient identities but will contain diagnosis (signs/symptoms), interventions including technical observations, diagnostic tests/results, and patient outcomes. Information about the recording device including device serial numbers, device model numbers, date of the event, and country/state of the event will be annotated with the data.
Time frame: Every 6 months
Access criteria: Data Archive for the BRAIN Initiative (DABI) - invasive human neurophysiology (including EEG, ECoG, LFP, single unit)
Data sharing details ↗ · www.dandiarchive.org
Ran from Sep 2021 to primary completion in Aug 2025, 47 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 47 months is close to that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.